1AM OB,Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline[ J]. Neurosci Lett,2004 ,355 (3) : 169-172.
2Jack J. Chen , Anh-Vuong Ly. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease[ J]. American Journal of Health-System Pharmacy, 2006,63 (10) :915-928.
3Abu-Raya S, Eran Blaugrund, Victoria Trembovler, et al. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation[ J]. J Neurosci Res, 1999,58(3) : 456-463.
4Yogev-Falach M, Amit T, Bar-Am O, et al. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing[ J]. FASEB J,2003,17:2325-2327.
5W. Maruyama, T. Takahashi, M. Youdim, et al. The anti-parkinson drug rasagiline, prevents apoptotic DNA damage induced by peroxynltrite in human dopamlnergic neuroblastoma SH-SYSY cells [ J]. J Neurosci Res,2002,109(4) :467-481.
6Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial[ J ]. Lancet,2005,365 (9463) :947-954.
7Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study[J]. Arch Neurol,2005 ,62(2) :241-248.
8Stem MB, Marek KL, Friedman J, et al. Double-blind, randomized,controlled trial of rasagiline as monotherapy in early Parkinson's disease patients [ J ]. Movement Disorders,2004,19 ( 8 ) :916-923.
9Robert Hauser , Theresa Zesiewicz. Advances in the Pharmacologic Management of Early Parkinson Disease [ J]. The Neurologist, 2007, 13 (3) :126-132.
10Thebaul JJ,Guillaume M,Llevy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline : a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy [J] ,2004,24 (10) :1295-1305.
3Teismann P,Schulz JB.Celluar pathology of Parkinson's disease:astrocytes,microglia and inflammation[J].Cell Tissue Res,2004;318(1):149-61.
4Baquet ZC,Bickford PC,Jones KR.Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta[J].Neuroscience,2005;25(26):6251-9.
5Yan Q,Matheson C,Sun J,et al.Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression[J].Exp Neurol,1994;127(1):23-36.
7Mandel S,Weinreb O,Amit T,et al.Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives[J].Brain Res Rev,2005;48(2):379-87.
8Presgraves SP,Borwege S,Millan MJ,et al.Involvement of dopamine D(2)/D(3)receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells[J].Exp Neurol,2004;190(1):157-70.
9Clarke CE,Guttman M.Dopamine agonist monotherapy in Parkinson's disease[J].Lancet,2002;360(9347):1767-9.
10Canales JJ,Capper-Loup C,Hu D,et al.Shifts in striatal responsivity evoked by chronic stimulation of dopamine and glutamate systems[J].Brain,2002;125(Pt 10):2353-63.
